These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 32983144)

  • 21. Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.
    Stelljes M; Strothotte R; Pauels HG; Poremba C; Milse M; Specht C; Albring J; Bisping G; Scheffold C; Kammertoens T; Oelmann E; Silling G; Berdel WE; Kienast J
    Blood; 2004 Aug; 104(4):1210-6. PubMed ID: 15090450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
    Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
    Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reconstitution of self-tolerance after hematopoietic stem cell transplantation.
    Hess AD
    Immunol Res; 2010 Jul; 47(1-3):143-52. PubMed ID: 20066509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoimmunity following haematopoietic stem-cell transplantation.
    Daikeler T; Tyndall A
    Best Pract Res Clin Haematol; 2007 Jun; 20(2):349-60. PubMed ID: 17448966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of graft-versus-autoimmune (GVA) disease effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Kojima R; Kami M; Kim SW; Murashige N; Kishi Y; Hori A; Imataki O; Hamaki T; Sakiyama M; Masuo S; Fujisawa Y; Makimoto A; Heike Y; Tanosaki R; Takaue Y
    Bone Marrow Transplant; 2003 Aug; 32(4):439-42. PubMed ID: 12900783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.
    Larsen ME; Kornblit B; Larsen MV; Masmas TN; Nielsen M; Thiim M; Garred P; Stryhn A; Lund O; Buus S; Vindelov L
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1370-81. PubMed ID: 20353833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pre-transplantation thymic function is associated with the risk of acute graft versus host disease and cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation.
    Yang X; Sun Y; Zhang S; Yang H; Wei J; He Y; Yang D; Jiang E; Han M; Qin X; Feng S
    Hematology; 2018 Jan; 23(1):30-37. PubMed ID: 28532344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.
    Yeh AC; Brunner AM; Spitzer TR; Chen YB; Coughlin E; McAfee S; Ballen K; Attar E; Caron M; Preffer FI; Yeap BY; Dey BR
    Biol Blood Marrow Transplant; 2014 May; 20(5):730-4. PubMed ID: 24530972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reconstitution of adaptive and innate immunity following allogeneic hematopoietic stem cell transplantation in humans.
    Peggs KS
    Cytotherapy; 2006; 8(5):427-36. PubMed ID: 17050247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.
    Finke J; Brugger W; Bertz H; Behringer D; Kunzmann R; Weber-Nordt RM; Kanz L; Mertelsmann R
    Bone Marrow Transplant; 1996 Dec; 18(6):1081-6. PubMed ID: 8971376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alloantigen expression on malignant cells and healthy host tissue influences graft-versus-tumor reactions after allogeneic hematopoietic stem cell transplantation.
    Robert S; Albring JC; Frebel K; Opitz C; Urh J; Wolf C; Heinrich C; Berdel WE; Stelljes M
    Bone Marrow Transplant; 2018 Jul; 53(7):807-819. PubMed ID: 29362503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
    Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
    Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress toward production of immunologic tolerance with no or minimal toxic immunosuppression for prevention of immunodeficiency and autoimmune diseases.
    Good RA
    World J Surg; 2000 Jul; 24(7):797-810. PubMed ID: 10833246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
    Michallet M; Dhedin N; Michallet AS
    Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation.
    Hosseini E; Schwarer AP; Ghasemzadeh M
    Iran J Allergy Asthma Immunol; 2012 Mar; 11(1):15-21. PubMed ID: 22427472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoimmune hematological diseases following haploidentical donor hematopoietic stem cell Transplant compared with matched sibling and unrelated donor.
    Lv W; Fan Z; Huang F; Xu N; Xuan L; GuopanYu ; Jiang Q; Zhou H; Lin R; Zhang X; Sun J; Liu Q
    Oncotarget; 2017 Apr; 8(16):26505-26514. PubMed ID: 28460445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
    Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
    Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina.
    Basquiera AL; Pizzi S; Correas AG; Longo PG; Goldman WC; Prates MV; Formisano S; Kusminisky G; Feldman L; Berretta AR; García JJ; Staciuk R
    Pediatr Blood Cancer; 2015 Jan; 62(1):153-7. PubMed ID: 25264233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
    Resnick IB; Shapira MY; Slavin S
    Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients.
    Sanz J; Arriaga F; Montesinos P; Ortí G; Lorenzo I; Cantero S; Puig N; Moscardó F; de la Rubia J; Sanz G; Sanz MA
    Bone Marrow Transplant; 2007 May; 39(9):555-61. PubMed ID: 17351645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.